NEWS HIGHLIGHTSMedia Articles Related to Vaniqa (Eflornithine)
Also In Global Health News: Sleeping Sickness; Aid For Philippines; U.S., China In Africa; Polio Eradication In Afghanistan; Ethiopia Famine
Source: Health News from Medical News Today [2009.11.19]
Lancet Infectious Diseases Examines Hold-Ups In Implementation Of Sleeping Sickness Therapy Lancet Infectious Diseases Newsdesk examines how despite evidence that a new therapy to treat sleeping sickness, called nifurtimox-eflornithine (NECT) is a step forward in treating the
Improved Treatment For Sleeping Sickness Now Available
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2009.11.01]
NECT (Nifurtimox-Eflornithine Combination Therapy), the first new treatment in 25 years against Human African trypanosomiasis (HAT) or sleeping sickness, is now available. Endemic countries have now begun the process of ordering the new combination treatment and kits through the World Health Organization (WHO). Developed by DNDi and its partners, NECT cuts the cost of treatment by half and significantly reduces the burden on health workers.
Published Studies Related to Vaniqa (Eflornithine)
Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. [2009.07.04]
BACKGROUND: Human African trypanosomiasis (HAT; sleeping sickness) caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients with second-stage disease are toxic, ineffective, or impractical. We assessed the efficacy and safety of nifurtimox-eflornithine combination therapy (NECT) for second-stage disease compared with the standard eflornithine regimen... INTERPRETATION: The efficacy of NECT is non-inferior to that of eflornithine monotherapy. Since this combination treatment also presents safety advantages, is easier to administer (ie, infusion every 12 h for 7 days vs every 6 h for 14 days), and potentially protective against the emergence of resistant parasites, it is suitable for first-line use in HAT control programmes. FUNDING: Medecins Sans Frontieres (Dutch section), Medecins Sans Frontieres International, and the Drugs for Neglected Diseases Initiative.
Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. [2007.12.01]
BACKGROUND: Human African trypanosomiasis caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients with second-stage disease are either highly toxic or impracticable in field conditions. We compared the efficacy and safety of the nifurtimox-eflornithine drug combination with the standard eflornithine regimen for the treatment of second-stage disease... CONCLUSIONS: The nifurtimox-eflornithine combination appears to be a promising first-line therapy for second-stage sleeping sickness. If our findings are corroborated by ongoing findings from additional sites (a multicenter extension of this study), the new nifurtimox-eflornithine combination therapy will mark a major and multifaceted advance over current therapies.
A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. [2007.07]
BACKGROUND AND OBJECTIVE: Although there are a multitude of therapeutic modalities for removing unwanted facial hair in women, there is very little information on using the newer medical treatment approaches in combination. This study was designed to determine whether topical eflornithine can enhance the efficacy of laser hair removal... CONCLUSIONS: On the basis of both investigator and patient assessments and hair count analysis, we have demonstrated that the addition of eflornithine to laser hair removal results in a more rapid and complete reduction of unwanted facial hair in women when the combination is used for up to 6 months.
The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness. [2004.06]
OBJECTIVE: To investigate the plasma, cerebrospinal fluid (CSF) levels and pharmacokinetics of eflornithine (DFMO) in patients with late-stage T.b. gambiense sleeping sickness who were treated with an oral DFMO at 100 mg/kg or 125 mg/kg body weight every 6 h for 14 days... CONCLUSION: Oral DFMO at the dose of 125 mg/kg body weight given every 6 h for 14 days may not produce adequate therapeutic plasma and CSF levels for patients with late-stage T.b. gambiense sleeping sickness.
Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. [2000]
OBJECTIVE: A randomized controlled trial was conducted to determine whether 7 days of intravenous eflornithine (100 mg/kg every 6 h) was as effective as the standard 14-day regimen in the treatment of late-stage Trypanosoma brucei gambiense trypanosomiasis... For new cases, a 7-day course is inferior to the standard 14-day regimen and cannot be recommended.
Clinical Trials Related to Vaniqa (Eflornithine)
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis [Active, not recruiting]
Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy [Completed]
RATIONALE: Drugs used in chemotherapy, such as eflornithine, work in different ways to stop
tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of
prostate cancer cells. Drugs used in hormone therapy, such as bicalutamide, may fight
prostate cancer by stopping the adrenal glands from producing androgens. Combining
eflornithine with bicalutamide may kill more tumor cells.
PURPOSE: Randomized phase II trial to compare the effectiveness of neoadjuvant eflornithine
and bicalutamide with that of eflornithine alone, bicalutamide alone, and no neoadjuvant
therapy in treating patients who are undergoing brachytherapy or radical prostatectomy for
localized prostate cancer.
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis [Terminated]
The treatment human African trypanosomiasis (HAT) in the meningoencephalitic phase relies on
two molecules officially registered: melarsoprol, the most commonly used, has a poor safety
profile and is becoming ineffective due to parasite resistance; and eflornithine, with better
tolerance but more complicated and expensive to implement in endemic countries. nifurtimox,
registered only for Chagas' disease but used off-label since the 1970’s in series of cases of
HAT, is at present the only other available alternative.
The very limited number of compounds available, the lack of prospects for the development of
new products and the emergence of resistance are arguments for the use of therapeutic
combinations.
This study evaluates the efficacy and safety of three drug combination therapies:
melarsoprol-nifurtimox, melarsoprol-eflornithine and eflornithine-nifurtimox.
Aspirin and Eflornithine in Treating Patients at High Risk for Colorectal Cancer [Recruiting]
Rationale: Chemoprevention is the use of certain drugs to keep cancer from forming. The use
of aspirin and eflornithine may prevent colorectal cancer.
Purpose: This phase II trial is studying how well giving aspirin together with eflornithine
works in treating patients at high risk for colorectal cancer.
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda [Terminated]
This case series study follows on a terminated randomised clinical trial in a nearby location
of Uganda, in which the combination of eflornithine + nifurtimox showed very promising
efficacy and safety. The study's purpose is to evaluate the efficacy and safety of this
combination in a larger group of late-stage Human African trypanosomiasis (sleeping sickness)
patients.
|
